MBX Biosciences says Phase 2 data show once-weekly canvuparatide sustains 57% responder rate at one year in hypoparathyroidism

MBX Biosciences, Inc.

MBX Biosciences, Inc.

MBX

0.00
  • MBX Biosciences reported full Phase 2 Avail results, with new one-year open-label extension data for once-weekly canvuparatide in chronic hypoparathyroidism.
  • Data showed sustained disease control over a year, supporting physiologic PTH replacement with reduced reliance on standard supplements.
  • Kidney function and bone activity trends stayed consistent with restored PTH action, reinforcing the broader clinical profile beyond calcium control.
  • Safety remained generally favorable over a year, with no new safety signals reported during the extension period.
  • One-year extension results were set for presentation June 12 at ENDO 2026; full 12-week Phase 2 results were scheduled for June 13.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. MBX Biosciences Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606120700PRIMZONEFULLFEED9745957) on June 12, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.